Effect of Magnesium on Dose of Rocuronium for Deep Neuromuscular Blockade

Status Completed

Clinical Trial Summary

It is well known that magnesium enhances the effect of neuromuscular blocking agents such as rocuronium. However, it is not known how much magnesium can reduce neuromuscular blocking agents in maintaining deep neuromuscular blockade. Through this study, the investigators will quantitatively analyze the rocuronium saving effect of magnesium.

Clinical Trial Description

It is well known that magnesium potentiate the effect of neuromuscular blocking agents. It prolonged the duration of rocuronium and reduces the onset time of rocuronium. Magnesium acts on motor end plate, where magnesium reduces the release of prejunctional acetylcholine, thereby decreasing the muscle membrane excitability. However, the quantitative rocuronium saving effect of magnesium is not clear. This study's hypothesis is that magnesium would reduce the amount of rocuronium. And the investigators want to evaluate how much magnesium can reduce the amount of rocuronium. Secondary outcome is the effects of magnesium on recovery time, postoperative pain, nausea and vomiting. ;

Study Design

Related Conditions & MeSH terms

Magnesium Sulfate Causing Adverse Effects in Therapeutic Use
Neuromuscular Blockade

Clinical Trial Details

NCT number	NCT04013243
Study type	Interventional
Source	Seoul National University Bundang Hospital
Contact
Status	Completed
Phase	N/A
Start date	April 26, 2019
Completion date	July 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05558969` - The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex	N/A
Completed	`NCT03168308` - Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients	Phase 4
Not yet recruiting	`NCT03978780` - Erector Spinae Block vs. Placebo Block Study	N/A
Completed	`NCT02912039` - Electromyographic Assessment of the TetraGraph in Normal Volunteers
Completed	`NCT02892045` - Mindray Neuromuscular Transmission Transducer
Completed	`NCT03427385` - Minimum Local Anesthetic Dose for Adductor Canal Block	N/A
Completed	`NCT01450813` - The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy	N/A
Completed	`NCT00535496` - Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)	Phase 3
Recruiting	`NCT05794503` - Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex	Early Phase 1
Not yet recruiting	`NCT05993390` - Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients	N/A
Recruiting	`NCT04609410` - Bleeding in Laparoscopic Liver Surgery	N/A
Terminated	`NCT03649672` - The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor	N/A
Completed	`NCT05687253` - Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery	Phase 2
Completed	`NCT05474638` - Comparison of Mechanomyographic 100 Versus 200 Hz 5 Second Tetanic Fade Ratios During Neuromuscular Block Recovery	N/A
Completed	`NCT05120999` - Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
Completed	`NCT03572413` - The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.	Phase 4
Completed	`NCT03608436` - The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery	Phase 4
Recruiting	`NCT02930629` - Residual Block in Postoperative Anaesthetic Care Unit	N/A
Completed	`NCT02932254` - Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex	Phase 4
Completed	`NCT01828385` - Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex	Phase 4